Drugs / Sodium tanshinone IIA sulfonate
Sodium tanshinone IIA sulfonate
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03591471 | Sep 2014 → Dec 2018 | immunoglobulin A vasculitis | Henan University of Traditional Chinese Medicine | Unknown | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT01637675 | May 2013 → Dec 2014 | lung disorder, pulmonary arterial hypertension | The First Affiliated Hospital of Guangzhou Medical University | Unknown | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT02524964 | Dec 2015 → Dec 2016 | acute myocardial infarction | Guangdong Provincial Hospital of Traditional Chinese Medicine | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | sodium tanshinone IIA sulfonate | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02524964 ↗ |
| Known as | Sulfotanshinone Sodium | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03591471 ↗ |
| Known as | tanshinone IIa sodium sulfonate | “The treatment group received tripterygium glycosides (TGs), tanshinone IIa sodium sulfonate injection, and Chinese herbs selected based on syndrome differentiation in TCM.” PMID 31464626 ↗ Aug 2019 |
| Modality | Small molecule | — CHEMBL1621346 ↗ |
| Route | Intravenous | “250ml iv drip once a day for 8 weeks” NCT01637675 ↗ |